Page last updated: 2024-10-24

mesenchymal to epithelial transition involved in metanephric renal vesicle formation

Definition

Target type: biologicalprocess

A transition where a mesenchymal cell establishes apical/basolateral polarity,forms intercellular adhesive junctions, synthesizes basement membrane components and becomes an epithelial cell that will contribute to the shaping of the metanephric renal vesicle. [GOC:mtg_kidney_jan10]

Metanephric renal vesicle formation involves a complex process of mesenchymal to epithelial transition (MET). This transition is critical for the development of the nephron, the functional unit of the kidney. Here's a detailed description:

1. **Mesenchymal Cells:** The process begins with mesenchymal cells, undifferentiated cells that are derived from the metanephric mesenchyme. These cells have a loose, fibroblast-like morphology and express specific markers such as Pax2 and Wnt4.

2. **Induction by the Ureteric Bud:** The ureteric bud, an outgrowth from the Wolffian duct, interacts with the metanephric mesenchyme, triggering the MET process. This interaction is mediated by reciprocal signaling pathways, including GDNF (glial cell line-derived neurotrophic factor) from the mesenchyme and RET (receptor tyrosine kinase) from the ureteric bud.

3. **Epithelial Commitment and Cell Aggregation:** The inductive signals from the ureteric bud initiate a cascade of events that cause mesenchymal cells to commit to an epithelial fate. They begin to express epithelial markers like E-cadherin and ZO-1, and their morphology changes from fibroblast-like to rounded, epithelial-like cells. These cells then aggregate around the tips of the ureteric bud branches, forming epithelial spheres known as renal vesicles.

4. **Polarization and Lumen Formation:** As the renal vesicles form, the epithelial cells undergo polarization. The apical surfaces of the cells face the lumen of the vesicle, while the basolateral surfaces face the surrounding mesenchyme. This polarization is crucial for the formation of a functional lumen within the vesicle.

5. **Differentiation and Nephron Development:** The renal vesicles further differentiate into various segments of the nephron, including the glomerulus, proximal tubule, loop of Henle, and distal tubule. This differentiation involves the expression of specific genes and the formation of specialized cell types within the nephron.

The mesenchymal to epithelial transition during metanephric renal vesicle formation is a tightly regulated process involving complex signaling pathways, transcription factors, and cell-cell interactions. It is essential for the proper development of the kidney and its ability to filter blood and produce urine.'
"

Proteins (1)

ProteinDefinitionTaxonomy
Smoothened homologA protein smoothened that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q99835]Homo sapiens (human)

Compounds (15)

CompoundDefinitionClassesRoles
cyclopaminepiperidinesglioma-associated oncogene inhibitor
pd 173955PD 173955: inhibits src family-selective tyrosine kinase; structure in first sourcearyl sulfide;
dichlorobenzene;
methyl sulfide;
pyridopyrimidine
tyrosine kinase inhibitor
purmorphaminepurmorphamine : A member of the class of purines that is purine substituted at C-2 by a 1-naphthyloxy group, at C-4 by a 4-morpholinophenylamino group, and at N-9 by a cyclohexyl group.

purmorphamine: structure in first source
aromatic ether;
morpholines;
purines;
secondary amino compound
osteogenesis regulator;
SMO receptor agonist
cur 61414CUR 61414: inhibits the hedehog signaling pathway; structure in first source
abt 869aromatic amine;
indazoles;
phenylureas
angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
lde225sonidegib : A member of the classo of biphenyls that is the amide obtained by formal condensation of the carboxy group of 2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxylic acid with the amino group of 6-(2,6-dimethylmorpholin-4-yl)pyridin-3-amine. Used (as its phosphate salt) for treatment of locally advanced basal cell carcinoma.

sonidegib: specific Smoothened/Smo antagonist
aminopyridine;
aromatic ether;
benzamides;
biphenyls;
morpholines;
organofluorine compound;
tertiary amino compound
antineoplastic agent;
Hedgehog signaling pathway inhibitor;
SMO receptor antagonist
gdc 0449HhAntag691: inhibits the hedgehog pathway and ABC transporters; has antineoplastic activitybenzamides;
monochlorobenzenes;
pyridines;
sulfone
antineoplastic agent;
Hedgehog signaling pathway inhibitor;
SMO receptor antagonist;
teratogenic agent
N-[[3-fluoro-4-[[2-(1-methyl-4-imidazolyl)-7-thieno[3,2-b]pyridinyl]oxy]anilino]-sulfanylidenemethyl]-2-phenylacetamidethioureas
ipi-926IPI-926: a semisynthetic derivative of cyclopamine that is a smoothened inhibitor with antineoplastic activity; structure in first sourcepiperidines
gsk 1363089GSK 1363089: a multikinase inhibitor that acts on Met, RON, Axl, and VEGFR; structure in first sourcearomatic ether
tak-441TAK-441: structure in first source
ly2940680
3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylureaBGJ-398 : A member of the class of phenylureas that is urea in which a hydrogen attached to one of the nitrogens is replaced by a 2,6-dichloro-3,5-dimethoxyphenyl group, while the hydrogens attached to the other nitrogen are replaced by a methyl group and a 6-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl group. It is a potent and selective fibroblast growth factor receptor inhibitor.

infigratinib: structure in first source
aminopyrimidine;
dichlorobenzene;
N-alkylpiperazine;
N-arylpiperazine;
phenylureas
antineoplastic agent;
fibroblast growth factor receptor antagonist
cep-32496agerafenib: inhibitor of RAF family kinases; structure in first source
pf-52748571-(4-(5'-chloro-3,5-dimethyl-2,4'-bipyridin-2'-yl)piperazin-1-yl)-3-(methylsulfonyl)propan-1-one: a potent and selective Smoothened antagonist that penetrates the blood-brain barrier; structure in first source